Skip to main content

Advertisement

Log in

Evaluating the expression of CARMA3 as a prognostic tumor marker in renal cell carcinoma

  • Research Article
  • Published:
Tumor Biology

Abstract

Increased expression of CARMA3 has been reported to be involved in tumorigenesis and tumor progression of several cancer types. The aim of our study is to investigate the prognostic role of CARMA3 expression in patients with renal cell carcinoma (RCC). Real-time quantitative PCR was performed to detect CARMA3 mRNA expression level in 31 paired samples of RCC and adjacent noncancerous renal tissues. Subsequently, extensive immunohistochemistry was performed to detect CARMA3 protein expression in 114 RCC cases. Clinicopathological data for these patients were evaluated. The prognostic significance was assessed using the Kaplan–Meier survival estimates and log-rank tests. CARMA3 mRNA expression was significantly higher in RCC tissues compared with adjacent noncancerous renal tissues (3.525 ± 1.233 vs. 1.512 ± 0.784, P < 0.001). In addition, high CARMA3 expression in RCC tissues was significantly associated with tumor size (P = 0.026), histological differentiation (P = 0.039), tumor stage (P = 0.006), and the presence of metastasis (P < 0.001). Moreover, Kaplan–Meier analysis showed that patients with high CARMA3 expression also had a significantly poorer prognosis than those with low CARMA3 expression (log-rank test, P < 0.001). Furthermore, multivariate analysis illustrated that CARMA3 overexpression might be an independent prognostic indicator for the survival of patients with RCC. In conclusion, this work shows that CARMA3 may serve as a novel and prognostic marker for RCC and play a role during the development and progression of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. doi:10.3322/caac.20073.

    Article  PubMed  Google Scholar 

  2. Tolia BM, Whitmore Jr WF. Solitary metastasis from renal cell carcinoma. J Urol. 1975;114:836–8.

    PubMed  CAS  Google Scholar 

  3. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34:193–205. doi:10.1016/j.ctrv.2007.12.001.

    Article  PubMed  Google Scholar 

  4. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353(23):2477–90. doi:10.1056/NEJMra043172.

    Article  PubMed  CAS  Google Scholar 

  5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–90. doi:10.1200/JCO.2008.20.1293.

    Article  PubMed  CAS  Google Scholar 

  6. Stilo R, Liguoro D, Di Jeso B, Formisano S, Consiglio E, Leonardi A, et al. Physical and functional interaction of CARMA1 and CARMA3 with Ikappa kinase gamma-NFkappaB essential modulator. J Biol Chem. 2004;279:34323–31. doi:10.1074/jbc.M402244200.

    Article  PubMed  CAS  Google Scholar 

  7. Grabiner BC, Blonska M, Lin PC, You Y, Wang D, Sun J, et al. CARMA3 deficiency abrogates G protein-coupled receptor-induced NF-{kappa}B activation. Genes Dev. 2007;21:984–96. doi:10.1101/gad.1502507.

    Article  PubMed  CAS  Google Scholar 

  8. McAllister-Lucas LM, Ruland J, Siu K, Jin X, Gu S, Kim DS, et al. CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc Natl Acad Sci U S A. 2007;104:139–44. doi:10.1073/pnas.0601947103.

    Article  PubMed  CAS  Google Scholar 

  9. Borthakur A, Bhattacharyya S, Alrefai WA, Tobacman JK, Ramaswamy K, Dudeja PK. Platelet-activating factor-induced NF-kappaB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent. Inflamm Bowel Dis. 2010;16:593–603. doi:10.1002/ibd.21092.

    Article  PubMed  Google Scholar 

  10. Marasco D, Stilo R, Sandomenico A, Monti SM, Tizzano B, de Capua A, et al. Generation and functional characterization of a BCL10-inhibitory peptide that represses NF-kappaB activation. Biochem J. 2009;422:553–61. doi:10.1042/BJ20090055.

    Article  PubMed  CAS  Google Scholar 

  11. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18:2195–224. doi:10.1101/gad.1228704.

    Article  PubMed  CAS  Google Scholar 

  12. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004;6:203–8. doi:10.1016/j.ccr.2004.09.003.

    Article  PubMed  CAS  Google Scholar 

  13. Mahanivong C, Chen HM, Yee SW, Pan ZK, Dong Z, Huang S. Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene. 2008;27:1273–80. doi:10.1038/sj.onc.1210746.

    Article  PubMed  CAS  Google Scholar 

  14. Jiang T, Grabiner B, Zhu Y, Jiang C, Li H, You Y, et al. CARMA3 is crucial for EGFR-induced activation of NF-κB and tumor progression. Cancer Res. 2011;71(6):2183–92. doi:10.1158/0008-5472.CAN-10-3626.

    Article  PubMed  CAS  Google Scholar 

  15. Rehman AO, Wang CY. CXCL12/SDF-1 alpha activates NF-kappaB and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex. Int J Oral Sci. 2009;1:105–18. doi:10.4248/IJOS.09059.

    Article  PubMed  Google Scholar 

  16. Miao Z, Zhao T, Wang Z, Xu Y, Song Y, Wu J, et al. CARMA3 is overexpressed in colon cancer and regulates NF-κB activity and cyclin D1 expression. Biochem Biophys Res Commun. 2012;425:781–7. doi:10.1016/j.bbrc.2012.07.152.

    Article  PubMed  CAS  Google Scholar 

  17. Li Z, Qu L, Dong Q, Huang B, Li H, Tang Z, et al. Overexpression of CARMA3 in non-small-cell lung cancer is linked for tumor progression. PLoS One. 2012;7:e36903. doi:10.1371/journal.pone.0036903.

    Article  PubMed  CAS  Google Scholar 

  18. Muriel López C, Esteban E, Berros JP, Pardo P, Astudillo A, Izquierdo M, et al. Prognostic factors in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2012;10:262–70. doi:10.1016/j.clgc.2012.06.005.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Guang-Li Wu or Fu-Li Wang.

Additional information

Guang-Li Wu, Jian-Lin Yuan, and Xu-Dong Huang contributed equally to this paper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, GL., Yuan, JL., Huang, XD. et al. Evaluating the expression of CARMA3 as a prognostic tumor marker in renal cell carcinoma. Tumor Biol. 34, 3431–3435 (2013). https://doi.org/10.1007/s13277-013-0917-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-0917-6

Keywords

Navigation